UA103025C2 - Твердая композиция лекарственного средства замедленного высвобождения - Google Patents

Твердая композиция лекарственного средства замедленного высвобождения

Info

Publication number
UA103025C2
UA103025C2 UAA201014638A UAA201014638A UA103025C2 UA 103025 C2 UA103025 C2 UA 103025C2 UA A201014638 A UAA201014638 A UA A201014638A UA A201014638 A UAA201014638 A UA A201014638A UA 103025 C2 UA103025 C2 UA 103025C2
Authority
UA
Ukraine
Prior art keywords
delayed release
solid pharmaceutical
pharmaceutical formulation
animals
particularly suitable
Prior art date
Application number
UAA201014638A
Other languages
English (en)
Ukrainian (uk)
Inventor
Венката-Рангарао КАНИКАНТИ
Томас Бах
Михаэль Тройбель
Гертраут Альтройтер
Мартина РЕХАГЕН
Аксель ШМИДТ
Original Assignee
Баер Интеллекчуел Проперти Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40846135&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA103025(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Баер Интеллекчуел Проперти Гмбх filed Critical Баер Интеллекчуел Проперти Гмбх
Publication of UA103025C2 publication Critical patent/UA103025C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Изобретение касается твердой композиции лекарственного средства с замедленным высвобождением активных веществ, пригодной, в частности, для лечения животных.
UAA201014638A 2008-05-07 2009-04-23 Твердая композиция лекарственного средства замедленного высвобождения UA103025C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102008022520A DE102008022520A1 (de) 2008-05-07 2008-05-07 Feste Arzneimittelformulierung mit verzögerter Freisetzung
PCT/EP2009/002951 WO2009135593A2 (de) 2008-05-07 2009-04-23 Feste arzneimittelformulierung mit verzögerter freisetzung

Publications (1)

Publication Number Publication Date
UA103025C2 true UA103025C2 (ru) 2013-09-10

Family

ID=40846135

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201014638A UA103025C2 (ru) 2008-05-07 2009-04-23 Твердая композиция лекарственного средства замедленного высвобождения

Country Status (29)

Country Link
US (2) US20110046072A1 (ru)
EP (1) EP2285359B1 (ru)
JP (1) JP5539966B2 (ru)
KR (1) KR101663501B1 (ru)
CN (1) CN102215824B (ru)
AR (1) AR071620A1 (ru)
AU (1) AU2009243759B2 (ru)
BR (1) BRPI0912428A2 (ru)
CA (1) CA2723553C (ru)
CL (1) CL2009001016A1 (ru)
CO (1) CO6311067A2 (ru)
DE (1) DE102008022520A1 (ru)
DK (1) DK2285359T3 (ru)
DO (1) DOP2010000331A (ru)
EC (1) ECSP10010588A (ru)
ES (1) ES2393169T3 (ru)
IL (1) IL208486A0 (ru)
MX (1) MX2010012025A (ru)
MY (1) MY159492A (ru)
NI (1) NI201000189A (ru)
NZ (1) NZ589017A (ru)
PE (1) PE20091949A1 (ru)
PL (1) PL2285359T3 (ru)
PT (1) PT2285359E (ru)
RU (1) RU2548733C9 (ru)
TW (1) TWI441644B (ru)
UA (1) UA103025C2 (ru)
UY (1) UY31788A (ru)
WO (1) WO2009135593A2 (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102258769B1 (ko) * 2011-10-14 2021-06-01 지엘팜텍주식회사 장용소화효소제 및 그 제조방법
CN104023710A (zh) * 2011-12-21 2014-09-03 拜耳知识产权有限责任公司 包含无定形艾默德斯的制剂
KR101400791B1 (ko) * 2012-10-04 2014-05-29 주식회사대성미생물연구소 동물용 복합 기능성 항생제 조성물
NZ708741A (en) 2012-12-19 2019-11-29 Bayer Animal Health Gmbh Tablets with improved acceptance and good storage stability
US10682337B2 (en) * 2015-03-03 2020-06-16 Kindred Biosciences, Inc. Compositions and methods for treatment and prevention of pyrexia in horses
CA2981489A1 (en) * 2015-04-02 2016-10-06 Merial, Inc. Anthelmintic combinations and methods of use thereof
CN107835818B (zh) 2015-05-20 2022-04-29 勃林格殷格翰动物保健美国公司 驱虫缩酚酸肽化合物
BR112018013369A2 (pt) 2015-12-28 2019-02-19 Merial, Inc. compostos depsipeptídicos anti-helmínticos
US20190142808A1 (en) 2016-06-09 2019-05-16 Ds Pharma Animal Health Co., Ltd. Sustained-release preparation composition for animals
EP3541789A1 (en) 2016-11-16 2019-09-25 Boehringer Ingelheim Animal Health USA Inc. Anthelmintic depsipeptide compounds
CN108888598A (zh) * 2018-08-01 2018-11-27 江西成必信生物科技有限公司 口服易吸收的布他磷及其制备方法
JP7268340B2 (ja) * 2018-12-06 2023-05-08 コニカミノルタ株式会社 ３ｄプリンター成形用樹脂組成物及びそれを用いた成形体とその製造方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2362539C2 (de) 1973-12-17 1986-05-07 Merck Patent Gmbh, 6100 Darmstadt 2-Acyl-4-oxo-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isochinoline, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
EP0134984B1 (en) 1983-07-16 1988-07-13 Beecham Group Plc Benzazepine and benzoxazepine derivatives
NO176766C (no) 1989-02-07 1995-05-24 Meiji Seika Kaisha Fremgangsmåte for fremstilling av en forbindelse med anthelmintaktivitet
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
NL9000238A (nl) * 1990-01-31 1991-08-16 Aesculaap Bv Veterinair fenytoinepreparaat.
DE4139963A1 (de) * 1991-12-04 1993-06-09 Basf Ag, 6700 Ludwigshafen, De Redispergierbares dispersionspulver aus n-vinylpyrrolidon-vinylacetat-copolymerisat, dessen herstellung und verwendung
NZ249588A (en) 1992-03-17 1996-08-27 Fujisawa Pharmaceutical Co Anthelmintic agent
SE501389C2 (sv) * 1992-04-24 1995-01-30 Leiras Oy Farmaceutiskt preparat och förfarande för dess framställning
DE4317458A1 (de) * 1992-06-11 1993-12-16 Bayer Ag Verwendung von cyclischen Depsipeptiden mit 18 Ringatomen zur Bekämpfung von Endoparasiten, neue cyclische Depsipeptide mit 18 Ringatomen und Verfahren zu ihrer Herstellung
AU666563B2 (en) * 1992-08-07 1996-02-15 Wisconsin Alumni Research Foundation Preparation of 19-nor-vitamin D compounds
SK281042B6 (sk) * 1992-09-18 2000-11-07 Yamanouchi Pharmaceutical Co., Ltd Prípravok hydrogélového typu s ustáleným uvoľňovaním
US5747448A (en) 1993-02-19 1998-05-05 Meiji Seika Kaisha, Ltd. Derivatives of cyclodepsipeptide PF 1022
DE4317457A1 (de) 1993-05-26 1994-12-01 Bayer Ag Octacyclodepsipeptide mit endoparasitizider Wirkung
DE4317432A1 (de) * 1993-05-26 1994-12-01 Bayer Ag Octacyclodepsipeptide mit endoparasitizider Wirkung
NZ271739A (en) 1993-09-06 1996-09-25 Fujisawa Pharmaceutical Co Cyclodepsipeptide compounds and pharmaceutical compositions thereof
DE4401389A1 (de) * 1994-01-19 1995-07-20 Bayer Ag Verwendung von cyclischen Depsipeptiden mit 12 Ringatomen zur Bekämpfung von Endoparasiten, neue cyclische Depsipeptide mit 12 Ringatomen und Verfahren zu ihrer Herstellung
DE4406025A1 (de) * 1994-02-24 1995-08-31 Bayer Ag Milchsäure-haltige cyclische Depsipeptide mit 18 Ringatomen als endoparasitizide Mittel und Verfahren zu ihrer Herstellung
US5747446A (en) * 1994-03-22 1998-05-05 Beth Israel Deaconess Medical Center Modified polypeptides with increased biological activity
HUT77530A (hu) * 1994-05-06 1998-05-28 Pfizer Inc. Azitromicint tartalmazó, szabályozott hatóanyag-felszabadítású dózisformák
DE4437198A1 (de) * 1994-10-18 1996-04-25 Bayer Ag Verfahren zur Sulfonylierung, Sulfenylierung und Phosphorylierung von cyclischen Depsipeptiden
ATE425973T1 (de) 1995-06-30 2009-04-15 Astellas Pharma Inc Depsipeptid-derivat, verfahren zu dessen herstellung und zwischenprodukt dafur
DE19531684A1 (de) * 1995-08-29 1997-03-06 Bayer Ag Verfahren zur Herstellung von Arzneimittelzubereitungen mit kontrollierter Freisetzung
ATE299871T1 (de) * 1995-09-22 2005-08-15 Meiji Seika Kaisha Neue zyklische depsipeptid pf1022 derivate
DE19545639A1 (de) 1995-12-07 1997-06-12 Bayer Ag Verfahren zur Herstellung von substituierten Arylmilchsäure-haltigen Cyclodepsipeptiden mit 24 Ringatomen
AUPP279698A0 (en) * 1998-04-03 1998-04-30 Sunscape Developments Limited Sustained release formulation
IT1303693B1 (it) * 1998-11-03 2001-02-23 Formenti Farmaceutici Spa Composizioni a rilascio controllato di metamizolo.
DE19920415A1 (de) * 1999-05-04 2000-11-09 Hexal Ag Metamizol enthaltende, kontrolliert freisetzende pharmazeutische Zusammensetzung
US20010053791A1 (en) * 2000-03-16 2001-12-20 Babcock Walter C. Glycogen phosphorylase inhibitor
DE10031044A1 (de) * 2000-06-26 2002-01-03 Bayer Ag Endoparasitizide Mittel zur freiwilligen oralen Aufnahme durch Tiere
JP4426286B2 (ja) * 2001-07-10 2010-03-03 テバ ファーマシューティカル インダストリーズ リミティド ０次、０次−二相性、上昇型又は下降型薬物放出のための薬物送達システム
US20030190343A1 (en) 2002-03-05 2003-10-09 Pfizer Inc. Palatable pharmaceutical compositions for companion animals
DE10212864B4 (de) * 2002-03-22 2005-12-22 Beiersdorf Ag Polymermatrizes umfassend ein Mischsystem zur Löslichkeitsvermittlung von pharmazeutischen Wirkstoffen, Verfahren zu deren Herstellung und deren Verwendung
US20040037869A1 (en) * 2002-08-16 2004-02-26 Douglas Cleverly Non-animal product containing veterinary formulations
EP1613353A1 (en) * 2003-04-02 2006-01-11 Boehringer Ingelheim International GmbH Pharmaceutical compositions for hepatitis c viral protease inhibitors
TR200300510A2 (tr) * 2003-04-18 2004-11-22 Sanovel �La� Sanay� Ve T�Caret A.�. Dağılan alendronat mikropartikül formülasyonu
US20050053658A1 (en) * 2003-09-09 2005-03-10 Venkatesh Gopi M. Extended release systems for macrolide antibiotics
US7396819B2 (en) * 2003-08-08 2008-07-08 Virbac Corporation Anthelmintic formulations
DE10351448A1 (de) * 2003-11-04 2005-06-09 Bayer Healthcare Ag Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften
KR20060125824A (ko) * 2003-12-01 2006-12-06 라이프사이클 파마 에이/에스 레르카니디핀을 포함한 약학적 조성물
DE10358525A1 (de) * 2003-12-13 2005-07-07 Bayer Healthcare Ag Endoparasitizide Mittel zur topischen Applikation
DE102004055316A1 (de) * 2004-11-16 2006-05-18 Bayer Healthcare Ag Verhinderung vertikaler Endoparasiten-Infektionen
AR055106A1 (es) * 2005-08-05 2007-08-08 Osmotica Pharmaceutical Argent Composicion farmaceutica solida de liberacion extendida que contiene carbidopa y levodopa
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
ATE502629T1 (de) * 2006-04-28 2011-04-15 Gruenenthal Gmbh Pharmazeutische kombination mit 3- (3- dimethylamino-1-ethyl-2-methyl-propyl) phenol und einem nsar
US20090196934A1 (en) * 2006-07-26 2009-08-06 Asahi Kasei Chemicals Corporation Spherical elementary granule and method for production thereof
DE102006044694A1 (de) * 2006-09-22 2008-03-27 Krewel Meuselbach Gmbh Perorale feste Schmerzmittelzubereitung
DE102007012644A1 (de) * 2007-03-16 2008-09-18 Bayer Healthcare Ag Stabilisierung von Vitamin B12

Also Published As

Publication number Publication date
RU2548733C2 (ru) 2015-04-20
MX2010012025A (es) 2010-12-07
US20150150985A1 (en) 2015-06-04
UY31788A (es) 2009-12-14
AU2009243759B2 (en) 2015-04-16
NI201000189A (es) 2011-08-10
DOP2010000331A (es) 2010-12-15
KR20110015592A (ko) 2011-02-16
CL2009001016A1 (es) 2010-08-13
CN102215824B (zh) 2015-06-03
JP2011519878A (ja) 2011-07-14
EP2285359A2 (de) 2011-02-23
MY159492A (en) 2017-01-13
PL2285359T3 (pl) 2013-01-31
US20110046072A1 (en) 2011-02-24
ES2393169T3 (es) 2012-12-19
NZ589017A (en) 2012-11-30
BRPI0912428A2 (pt) 2016-02-16
PE20091949A1 (es) 2009-12-25
KR101663501B1 (ko) 2016-10-07
CO6311067A2 (es) 2011-08-22
RU2548733C9 (ru) 2015-12-20
CA2723553A1 (en) 2009-11-12
AU2009243759A1 (en) 2009-11-12
EP2285359B1 (de) 2012-09-05
CA2723553C (en) 2016-08-30
HK1162936A1 (en) 2012-09-07
IL208486A0 (en) 2010-12-30
TWI441644B (zh) 2014-06-21
PT2285359E (pt) 2012-11-26
ECSP10010588A (es) 2010-12-30
DK2285359T3 (da) 2012-11-26
WO2009135593A2 (de) 2009-11-12
TW201010714A (en) 2010-03-16
WO2009135593A3 (de) 2011-01-06
AR071620A1 (es) 2010-06-30
DE102008022520A1 (de) 2009-11-12
JP5539966B2 (ja) 2014-07-02
RU2010149561A (ru) 2012-06-20
CN102215824A (zh) 2011-10-12

Similar Documents

Publication Publication Date Title
UA103025C2 (ru) Твердая композиция лекарственного средства замедленного высвобождения
EP2522653A4 (en) BIGUANIDE DERIVATIVE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE BIGUANIDE DERIVATIVE AS AN ACTIVE SUBSTANCE
IL225637A0 (en) The compositions, tablets containing such compositions, their use and a process for their preparation
WO2010021607A3 (en) Pharmaceutical formulation
AP2010005341A0 (en) Solid pharmaceutical dosage form
WO2011130615A3 (en) Preparation of lacosamide
IL208370A0 (en) Improved formulations for poorly permeable active pharmaceutical ingredients
IL211018A (en) Inhibitors, processes for making them, medicinal preparations containing them and their use
IL213452A0 (en) Phenylpyrimidone compounds, pharmaceutical compositions, preparation methods and uses thereof
EP2447253A4 (en) DIHYDROPYRIMIDIN COMPOUNDS AND MANUFACTURING METHOD, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
PH12012502082A1 (en) Combination of active loaded granules with additional actives
WO2011002422A3 (en) Solubility enhancing pharmaceutical formulation
EP2335697A4 (en) STABLE MEDICINAL PREPARATION WHOSE COLOR MODIFICATION IS ABOLISHED.
IL207205A0 (en) Triazolopyridazines as par1 inhibitors, their preparation and use as medicaments
PL2504331T3 (pl) Związek, jego nowe formy, zawierające je kompozycje farmaceutyczne i sposoby otrzymywania oraz zastosowanie
IL208788A (en) Pharmacy-based formulation
IL208151A0 (en) Long-term stable pharmaceutical preparation having the active ingredient glycerol trinitrate
IL212171A (en) 1-Phenylpyrol compounds, pharmaceuticals containing them and their use
EP2335698B8 (en) Pharmaceutical solid preparation having active ingredients separated by boundary therein
MX2011006721A (es) Formulacion farmaceutica de fenofibrato nanonizado.
IL213588A0 (en) Naphthyridine derivatives, their preparation and pharmaceutical compositions containing them
TR200909785A1 (tr) Aktif ajan olarak sefdinir içeren farmasötik kompozisyonlar.
ZA201005316B (en) 2-amino-2-phenyl-alkanol derivatives, their preparation and pharmaceutical compositions containing them
IL208957A0 (en) Pharmaceutical gallium compounds, composition and methods of preparation
IL189408A0 (en) Siva3, its preparation and pharmaceutical compositions containing it